FDA
-
healthSanofi Taps Belén Garijo: Pharma Regulatory Shifts and Nipah Virus Vaccine Advance
Sanofi appoints Belén Garijo as CEO, the FDA revises trial requirements, and progress accelerates on a Nipah virus vaccine, highlighting key pharma innovations in February 2026.
-
healthEli Lilly's Orforglipron Shows Promise in Weight Loss Drug Race
New clinical trial results suggest Eli Lilly's orforglipron may outperform oral semaglutide in glycemic control and weight reduction for type 2 diabetes.
-
healthEli Lilly's Orforglipron Pill Shows Superior Weight Loss in Trials
New oral weight-loss drug orforglipron demonstrates significant efficacy in clinical trials, outperforming existing oral semaglutide treatments.
-
healthAI and Digital Twins Revolutionize Rare Disease Research
AI-powered digital twins are transforming rare disease research, overcoming traditional trial limitations and accelerating the development of new treatments for patients.
-
healthBeware of Compounded GLP-1 Drugs: Risks and Realities
Understand the critical differences between FDA-approved and compounded GLP-1 medications. Protect your health from unregulated and potentially dangerous alternatives.
-
healthGilead Acquires Arcellx for $7.8 Billion to Boost Cancer Therapy Pipeline
Gilead Sciences is acquiring Arcellx for $7.8 billion, aiming to fast-track its CAR-T cancer therapy for multiple myeloma and enhance its technology platform.
-
healthFDA Overhauls Drug Approval: One Trial Now the Standard
The FDA ends its 'two-trial dogma' for new medicine approvals, aiming to reduce development costs and drug prices.
-
healthFDA Reverses Moderna Flu Shot Rejection Amidst Controversy
The FDA is now reviewing Moderna's mRNA flu vaccine application after an initial rejection, following a revised submission strategy and ongoing debate over mRNA technology.